In this interview from the 2012 American Society of Hematology (ASH) Annual Meeting Dr. Rainer Storb, a leader in the field of transplants for over 40 years at the Fred Hutchinson Cancer Center, discusses advances in using bone marrow transplant to treat acute myelogenous leukemia (AML). He talks about novel targeted agents such as sorafenib and AC220, which is a kinase inhibitor. Dr. Storb also describes the refinement of transplants to improve recovery. They no longer require the hospitalization of patients. Learn more about these advancements.